



CURRICULUM VITAE

Ramandeep K. Brar, MD, FACC, FHRS

Joined Los Alamitos Cardiovascular in 2006 | Partner since 2009
Pacemaker Clinic Director

5300 Katella Avenue, Los Alamitos, CA 90720

p: (562) 430-7533 | f: (562) 430-8055 | website: www.losalcardio.com

Specialties:	Cardiovascular Diseases, Cardiac Electrophysiology and Nuclear Cardiology
Board Certifications:	<ul style="list-style-type: none">• Certified Clinical Cardiac Electrophysiology American Board of Internal Medicine November 2010 (Recertification 2019)• Certified in Nuclear Cardiology Board of Nuclear Cardiology December 2007 (Recertification 2018)• Certified in Cardiovascular Disease American Board of Internal Medicine November 2006 (Recertification 2017)• Certified in Internal Medicine American Board of Internal Medicine August 2001 (Recertification 2020) <hr/> <ul style="list-style-type: none">• Expert Reviewer The Medical Board of California August 2014-Present

Research Experience:	<ul style="list-style-type: none"> AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome. Sub-Investigator 2019 Sponsor: CSL Behring LLC NCT03473223: https://clinicaltrials.gov/ct2/show/NCT03473223
	<ul style="list-style-type: none"> COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots). Sub-Investigator 2018 – Present Sponsor : Patient-Centered Outcomes Research Institute (PCORI) NCT03196349: https://clinicaltrials.gov/ct2/show/NCT03196349 NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. Principal Investigator 2019 Sponsor: Milestone Pharmaceuticals Inc. NCT03464019: https://clinicaltrials.gov/ct2/show/NCT03464019 NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301). Principal Investigator 2019 Sponsor: Milestone Pharmaceuticals Inc. NCT03635996: https://clinicaltrials.gov/ct2/show/NCT03635996 PARADISE MI: A multi-center, randomized, double-blind, activecontrolled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction. Sub-Investigator 2018 – Present Sponsor: Novartis NCT02924727: https://clinicaltrials.gov/ct2/show/NCT02924727

- **PEA-VALVE:** Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms. Sub-Investigator | 2018 – Present
Sponsor: Eko Devices
- **GALACTIC-HF:** Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
Sub-Investigator | 2017 – Present

Sponsor: Amgen

NCT02929329: <https://clinicaltrials.gov/ct2/show/NCT02929329>

- **PROVE-HF:** A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Sub-Investigator | 2017 – 2019
Sponsor: Novartis
NCT02887183: <https://clinicaltrials.gov/ct2/show/NCT02887183>
- **Barostim Therapy for Heart Failure (BeAT-HF):** The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
Sub-Investigator | 2016 – Present Sponsor: CVRx, Inc.
NCT02627196: <https://clinicaltrials.gov/show/NCT02627196>
- **MLHFQ Study:** Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
Sub-Investigator | 2016 – 2017
Sponsor: Gilead/ICON

- THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS):** A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
 Sub-Investigator | 2015 – Present
 Sponsor: AstraZeneca
 NCT01991795: <https://clinicaltrials.gov/show/NCT01991795>
- Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
 Sub-Investigator | 2015 – 2016
 Sponsor: Amgen, Evidera

- DECLARE-TIMI 58 Dapagliflozin Effect on Cardiovascular Events:** A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
 Sub-Investigator | 2013 – 2018
 Sponsor: AstraZeneca
 NCT01730534 | <http://clinicaltrials.gov/ct2/show/NCT01730534>
- ODYSSEY EFC11570:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome Sub-Investigator | 2013 – 2017
 Sponsor: Sanofi
 NCT01663402 | <http://clinicaltrials.gov/ct2/show/NCT01663402>
- SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.**
 Sub-Investigator | 2013 – 2017
 Sponsor: Yale University School of Medicine/NIH
 NCT01755052 | <http://clinicaltrials.gov/ct2/show/NCT01755052>

- **RivaroxAFL3003:** An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
Sub-Investigator | 2013 – 2014
Sponsor: Janssen Scientific Affairs/Johnson & Johnson
- **Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.**
Sub-Investigator | 2013
Sponsor: Tasly Pharmaceuticals
NCT0169580 | <http://clinicaltrials.gov/ct2/show/NCT0169580>
- **Cardiovascular Inflammation Reduction Trial (CIRT):** Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
Sub-Investigator | 2013 – 2018
Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women's Hospital/National Heart Lung and Blood Institute
NCT01594333 | <http://clinicaltrials.gov/ct2/show/NCT01594333>

- **User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE0159.**
Sub-Investigator | 2012
Sponsor: Alere San Diego
- **Mission® PT Coagulation Monitoring System Clinical Study.**
Sub-Investigator | 2012
Sponsor: ACON Laboratories, INC.
- **The “BRIDGE” Trial (1U01HL08675501A1):** Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
Sub-Investigator | 2012 – 2015
Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
NCT00786474 | <http://clinicaltrials.gov/ct2/show/NCT00786474>

- GLORIA-AF 1160.129:** Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
 Sub-Investigator | 2012 – Present
 Sponsor: Boehringer Ingelheim
 NCT01468701 | <http://clinicaltrials.gov/ct2/show/NCT01468701>
- BRADYCARE:** Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
 Principal Investigator | 2010 – 2012
 Sponsor: St. Jude Medical Center
 NCT01062126 | <http://clinicaltrials.gov/ct2/show/NCT01062126>
- The PROMISE Trial:** PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
 Sub-Investigator | 2010 – 2014
 Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
 NCT01174550 | <http://clinicaltrials.gov/ct2/show/record/NCT01174550>
- ORBIT-AF I and II:** Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
 Sub-Investigator | 2010 – 2017
 Sponsor: Janssen Scientific Affairs, LLC
 Collaborator: Duke Clinical Research
 NCT01165710 | <http://clinicaltrials.gov/ct2/show/NCT01165710>
 NCT01701817 | <http://clinicaltrials.gov/ct2/show/NCT01701817>

	<ul style="list-style-type: none"> • RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population. Principal Investigator 2008 – 2010 Sponsor: St. Jude Medical Center NCT00837798 http://clinicaltrials.gov/ct2/show/NCT00837798 • ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48). Sub-Investigator 2009 – 2015 Sponsor: Daiichi Sankyo Pharma Development NCT00781391 http://clinicaltrials.gov/ct2/show/record/NCT00781391 • FREEDOM: A Frequent Optimization Study the Quick Opt™ Method. Principal Investigator 2008 – 2010 Sponsor: St. Jude Medical Center NCT00418314 http://clinicaltrials.gov/ct2/show/NCT00418314
Current Hospital Appointments:	<ul style="list-style-type: none"> • Los Alamitos Medical Center 3751 Katella Avenue Los Alamitos, California 90720 • Memorial Care Health System Long Beach Memorial Medical Center 2801 Atlantic Avenue Long Beach, California 90801 • UCLA Ronald Reagan Medical Center 757 Westwood Plaza Los Angeles, CA 90095

Staff Positions & Committees:	<p><i>Los Alamitos Medical Center</i></p> <ul style="list-style-type: none"> • Director, Cardiac Electrophysiology- Effective January 2016 to present • Chair, Medicine- January 2016 to January 2020 • Chair, Physician Leadership Council- July 2014-August 2017 • Vice Chair, Medicine- January 2014-December 2015 • Vice Chair, Credentialing- January 2013 to present • Vice Chair, Peer Review Committee-May 2016 to present • Chair Performance Improvement Committee- January 2020 to present • Secretary Treasurer Medical Staff - January 2020 to December 2021 • Vice Chief of Staff-January 2022 to present
Professional Societies:	<ul style="list-style-type: none"> • American College of Cardiology (FACC) Fellow • Heart Rhythm Society (FHR) Fellow
Publications:	<ul style="list-style-type: none"> • Anthony P, Chandraratna N, Skeikh Y, Brar R, Kim D. "Feasibility of Continuous Cardiac Imaging Using a Novel Ultrasound Transducer." <i>Circulation: Journal of American Heart Association: Abstracts from the 71st Scientific Sessions</i>. • Anthony P, Chandraratna N, Skeikh Y, Brar R, Khan Z, Chen Q. "Continuous Recording of Pulmonary Artery Diastolic pressure and cardiac Output using a Novel Ultrasound Transducer." <i>Circulation: Journal of the American Heart Association: Abstracts from the 71st Scientific Sessions</i>. • Chandraratna P, Brar R, Agioian E, Vijaysekara S. "Using of a Novel Chest Wall Attachable Ultrasound Transducer for Continuous Bedside Monitoring of Left Ventricular Regional Wall Motion Abnormalities." • Anthony P, Chandraratna N, Brar R, Vijaysekaran S, Chen Q. "Feasibility of Continuous Transthoracic imaging Using a Novel Ultrasound Transducer." • Anthony N, Chandraratna N, Brar R, Vijaysekaran S, Sheikh Y. "Continuous Recording of Pulmonary Artery Diastolic Pressure and Cardiac Output Using a Novel Ultrasound Transducer." <i>Echocardiography</i>. • Brar R, Attai S, Brar PK, Butler M, Chandraratna P. "Echocardiographic Evaluation of Left Ventricular Systolic Function." <i>Cardiac Ultrasound Today</i> 2003; Vol 9: Number 5.

Education:	<ul style="list-style-type: none"> • Cardiac Electrophysiology Fellowship University of California, Los Angeles July 2005 – August 2006 • Cardiovascular Diseases Fellowship University of California, Irvine July 2002 – July 2005 • Chief Resident, Internal Medicine 3rd Year Cornell University Medical Center/ Wyckoff Heights Medical Center July 2000 – June 2001 • Residency Training Internal Medicine
	<p>Cornell University Medical Center/ Wyckoff Heights Medical Center July 1998 – June 2001</p> <ul style="list-style-type: none"> • Rotatory Internship Dayanand Medical College and Hospital Ludhiana, Punjab, India January 1996 – June 1997 • MBBS /MD Dayanand Medical College and Hospital Ludhiana Punjab, India August 1991 – December 1995
Educational Honors and Awards:	<ul style="list-style-type: none"> • Intern of the Year Department of Internal Medicine, June 1999 Cornell University Medical Center/ Wyckoff Heights Medical Center • Intern of the Month Department of Internal Medicine, August 1998 Cornell University Medical Center/ Wyckoff Heights Medical Center